Tropomodulin isolated from rabbit skeletal muscle inhibits actin filament formation by capping both the pointed and barbed ends of tropomyosin- and troponin-bound actin filaments.
Answers are grounded in this paper and cite their sources.
Does not yet alter clinical sarcomere management; extends in vitro thin-filament regulation models but leaves open in vivo cardiac translation.
Tropomodulin is a tropomyosin-binding protein, originally isolated from human erythrocytes. Tropomodulin is currently regarded as the sole actin pointed-end capping protein [Weber, A., Pennise, C.R., Babcock, G.G. & Fowler, V.M. (1994) J. Cell Biol. 127, 1627-1635]. This work first describes a procedure for the purification of tropomodulin from rabbit skeletal muscle. Tropomodulin almost completely inhibited filament formation of actin in the presence of tropomyosin and troponin. For the maximal inhibition of actin polymerization, approximately 0.10, 0.12 and 0.003 mol of tropomyosin, troponin and tropomodulin per mol of actin were required, respectively. Fluorescence-intensity measurements, electron-microscopy and sedimentation experiments revealed that only very short fragments and amorphous aggregates, but not filaments, were formed when actin was copolymerized with tropomyosin, troponin and tropomodulin by the addition of 50 mM KCl at pH 8.0. The effects of tropomyosin, troponin and tropomodulin were more remarkable on Ca-actin than on Mg-actin. It appears that tropomodulin caps both the pointed and barbed ends of tropomyosin- and troponin-bound actin filaments.
No takes yet. Share an insight, caveat, or question.
Kimura et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: